This reaction is accompanied by hypermethylated endogenous retrovirus (ERV) genes, and in patients with melanoma receiving immune checkpoint therapy—specifically, anti-CTLA4—the viral defense signature is correlated with a long-lasting clinical response. The gene discussed is CTLA4; the disease is melanoma.